A previous multicenter study of 67 cases of Stage I/II tubo-ovarian high-grade serous carcinoma with complete tubal sampling identified 7 cases in which there were only two disease sites, comprising tumor involving opposite adnexa with no extra-adnexal involvement. This study aimed to determine whether such low-stage extrauterine high-grade serous carcinomas with only two sites of involvement, located on opposite adnexa, have identical or different TP53 mutations in order to investigate their clonal relationship. DNA extracted from both sites of involvement was subjected to TP53 sequencing (n = 6) or sequencing of one site and mutation confirmation by droplet digital PCR for the other site (n = 1). Of the 7 cases analyzed, 1 case had unilateral serous tubal intraepithelial carcinoma with contralateral ovarian high-grade serous carcinoma, 3 had tubal high-grade serous carcinomas ( ± serous tubal intraepithelial carcinoma) with contralateral ovarian high-grade serous carcinoma, 2 had bilateral ovarian high-grade serous carcinomas with normal tubes, and 1 had bilateral fallopian tube high-grade serous carcinoma with normal ovaries. All 7 cases showed identical TP53 mutations in tumor from both disease sites. Therefore, these rare cases of high-grade serous carcinoma confined to opposite adnexa all show clonal identity between the two sites of involvement, suggesting unifocal origin and metastasis rather than multifocal origin. Our results suggest that serous tubal intraepithelial carcinoma or adnexal highgrade serous carcinoma can metastasize to the contralateral adnexa without peritoneal involvement. Given the clonal relationship between the two sites, such cases should be considered stage II, with stage I reserved for cases with unilateral and unifocal adnexal involvement. Furthermore, serous tubal intraepithelial carcinoma without invasion should be taken to constitute a disease site for staging purposes.
A previous multicenter study of 67 cases of Stage I/II tubo-ovarian high-grade serous carcinoma with complete tubal sampling identified 7 cases in which there were only two disease sites, comprising tumor involving opposite adnexa with no extra-adnexal involvement. This study aimed to determine whether such low-stage extrauterine high-grade serous carcinomas with only two sites of involvement, located on opposite adnexa, have identical or different TP53 mutations in order to investigate their clonal relationship. DNA extracted from both sites of involvement was subjected to TP53 sequencing (n = 6) or sequencing of one site and mutation confirmation by droplet digital PCR for the other site (n = 1). Of the 7 cases analyzed, 1 case had unilateral serous tubal intraepithelial carcinoma with contralateral ovarian high-grade serous carcinoma, 3 had tubal high-grade serous carcinomas ( ± serous tubal intraepithelial carcinoma) with contralateral ovarian high-grade serous carcinoma, 2 had bilateral ovarian high-grade serous carcinomas with normal tubes, and 1 had bilateral fallopian tube high-grade serous carcinoma with normal ovaries. All 7 cases showed identical TP53 mutations in tumor from both disease sites. Therefore, these rare cases of high-grade serous carcinoma confined to opposite adnexa all show clonal identity between the two sites of involvement, suggesting unifocal origin and metastasis rather than multifocal origin. Our results suggest that serous tubal intraepithelial carcinoma or adnexal highgrade serous carcinoma can metastasize to the contralateral adnexa without peritoneal involvement. Given the clonal relationship between the two sites, such cases should be considered stage II, with stage I reserved for cases with unilateral and unifocal adnexal involvement. Furthermore, serous tubal intraepithelial carcinoma without invasion should be taken to constitute a disease site for staging purposes. The theories regarding the development of extrauterine-high grade serous carcinoma have included origin from the ovarian surface epithelium, 1 from cortical inclusion cysts, 2 from the pelvic peritoneum in cases where there is minimal or no ovarian involvement (primary peritoneal high-grade serous carcinoma), 3 and multifocal origin within a field change. [4] [5] [6] In the past 10 years, however, the theory of origin from serous tubal intraepithelial carcinoma of the fallopian tube epithelium has gained wide acceptance. 7, 8 The SEE-FIM (Sectioning and Extensively Examining the FIMbriated end of the fallopian tube) protocol, with serial sectioning and submission of the entire fallopian tube, is now the standard of care in the pathological examination of extrauterine high-grade serous carcinoma, especially early-stage tumors. This practice has resulted in the identification of serous tubal intraepithelial carcinoma or small tubal mucosal high-grade serous carcinoma in a significant number of cases of sporadic high-grade serous carcinoma and has resulted in further understanding of the relationship between serous tubal intraepithelial carcinoma and high-grade serous carcinoma. [9] [10] [11] It can be summarized that there is accumulating and convincing evidence that most extrauterine highgrade serous carcinomas, both sporadic and hereditary, arise from the fallopian tube, with impact on disease classification. [12] [13] [14] [15] [16] Although most extrauterine high-grade serous carcinomas present at advanced stage, that is, stage III or IV, the minority of cases where tumor is confined to the pelvis offer unique insights into the earliest events in oncogenesis. In recent studies of incidentally detected high-grade serous carcinoma in non-high-risk women, all examples with a single site of tumor involvement were located in the fallopian tube mucosa, [9] [10] [11] arguably the strongest evidence supporting the tubal origin of extrauterine highgrade serous carcinoma in most cases. In this study, we examined cases selected based on the very uncommon scenario of the presence of high-grade serous carcinoma/serous tubal intraepithelial carcinoma involving only two anatomic sites, specifically with bilateral adnexal involvement. Our objective was to assess clonality in these cases based on comparison of TP53 mutations, and thereby to investigate whether these separate lesions on opposite adnexa were more likely to represent primary and metastatic tumor, or independent tumors arising from multifocal origin within a cancerized field.
Materials and methods

Study Cohort and Procedures
A previously reported series of 67 cases of FIGO stage I and II extrauterine high-grade serous carcinoma, 17 in which the tubes had been sampled entirely according to the SEE-FIM protocol, revealed 7 cases with only two sites of disease, specifically located on opposite adnexa. This was found to be a rare occurrence (10%) in low-stage cases. Blocks were retrieved for molecular studies from 6 of these 7 cases, and from one additional case reported after the initial study.
Tumor Enrichment and DNA Extraction
Serial sections of formalin-fixed, paraffin embedded tissue were made and one stained with hematoxylin and eosin. In 5 cases (cases 1-5), sufficient tumor was present in both foci to allow for sampling of the whole section, or manual macrodissection of unstained paraffin sections. In these cases, DNA was extracted using the QiaAMP formalin-fixed, paraffin embedded tissue DNA extraction kit (Qiagen). In the remaining two cases (cases 6 and 7) one focus was enriched by manual macrodissection of unstained paraffin sections (and DNA extracted as noted above), and the other focus was enriched through needle macrodissection of hematoxylin and eosin-stained sections (case 6) or laser-capture microdissection of hematoxylin and eosin-stained sections on an LMD7000 (Leica) laser microdissection microscope (case 7). The latter two specimens had DNA extracted using the Pico-Pure DNA extraction kit (Thermo-Fisher).
TP53 Sequencing
DNA from all cases (except the serous tubal intraepithelial carcinoma from case 7, see below) was subjected to amplicon-based next-generation sequencing 18 of the entire TP53 gene (Supplementary Table S1 for primer sequences). Sufficient DNA was available for orthogonal validation of variants, in both tumor foci in cases 1-5 and the larger lesions from cases 6 and 7, by Sanger sequencing. The serous tubal intraepithelial carcinoma focus for case 7 was too small to allow for nextgeneration sequencing but sufficient DNA was recovered for droplet digital PCR confirming the presence of the same TP53 alteration observed in the contralateral ovarian high-grade serous carcinoma.
Droplet Digital PCR
High-resolution droplet digital PCR with was performed using 5′ exonuclease assays ('TaqMan') with allele-specific dual-labeled probes corresponding to mutant c.743G4A (FAM reporter) and wild-type (HEX reporter) TP53 alleles (BioRad Laboratories; mutant assay dHsaCP2000107; wild-type assay dHsaCP2000108), both with nonfluorescent quencher. Hundreds of thousands of water-oil emulsion microdroplet PCR reactions were generated, each with a single template DNA molecule using the QX200 Droplet Generator (BioRad Laboratories). Emulsion droplets were subject to thermal cycling in a standard thermal cycler (Bio-Rad Tetrad 2) and, when bound, allelespecific probes were degraded by exonuclease activity of Taq, releasing the 5′ reporter from the 3′ quencher and resulting in fluorescence (normally suppressed by FRET). Fluorescence of the reporter channels was measured and plotted ( Figure 2 ). Digital counting of the number of mutant (FAM) or wild-type (HEX) fluorescing drops was performed with the QX200 Droplet Reader (Bio-Rad Laboratories) and directly representative of the allelic representation in the sample. The high count number and digital nature of the assay allow for exceptionally high sensitivity detection of mutant alleles.
Results
Details of the 7 cases are shown in Table 1 . The patients ranged in age from 45 to 65 years. Of the 7
Identical TP53 mutations in bilateral HGSC N Singh et al cases, 1 patient had unilateral serous tubal intraepithelial carcinoma with contralateral ovarian highgrade serous carcinoma, 3 had tubal high-grade serous carcinoma ( ± serous tubal intraepithelial carcinoma) with contralateral ovarian high-grade serous carcinoma, 2 had bilateral ovarian highgrade serous carcinoma with normal tubes, and 1 had bilateral fallopian tube high-grade serous carcinoma with normal ovaries. In accordance with inclusion criteria, there were no other sites of disease in these women, all of whom had been surgically staged. The sizes of the tubal high-grade serous carcinomas ranged from 7 to 140 mm, and the ovarian high-grade serous carcinomas ranged from 3 to 150 mm. All 7 cases showed abnormal mutationtype p53 expression on immunohistochemistry; this was a diffuse nuclear overexpression pattern in 6 cases and a complete absence ('null') pattern in one case. In the 6 cases with overexpression, the immunostaining pattern was identical in both tumor foci ( Figure 1 ). For the remaining case with a 'null' pattern in one ovary, there was insufficient residual tumor in the block from the contralateral ovary, following TP53 sequencing, to allow confirmation of a concordant pattern of expression.
Identical TP53 mutations were seen in the paired contralateral adnexal tumors of all seven cases, as shown in Table 1 . The serous tubal intraepithelial carcinoma lesion in case 7 gave a unique opportunity to examine what appeared in two dimensions, on the glass slide, as three distinct foci in the tubal fimbria ( Figure 2 ). Each was laser-capture microdissected individually and tested for the presence of the c.742C4T (p.W248R) variant observed in the contralateral ovarian high-grade serous carcinoma, using droplet digital PCR. All three foci were positive for the mutation.
Discussion
This is the first study to investigate the clonal relationship between sites of involvement by 'early' extrauterine high-grade serous carcinoma, confined to two sites on opposite adnexa. Based on the finding of identical TP53 mutations, our results demonstrate that these cases are clonal, a finding in keeping with the results of many previous studies that have demonstrated identical TP53 mutations in serous tubal intraepithelial carcinoma and disseminated high-grade serous carcinoma. 7, [19] [20] [21] [22] [23] TP53 mutation is an early and almost ubiquitous molecular event in extrauterine high-grade serous carcinoma. 24, 25 As mutations in TP53 are not confined to hot spots, but are spread throughout the gene, the finding of identical somatic TP53 mutations in high-grade serous carcinoma at two anatomic sites is compelling evidence that these are clonally related; in these early lesions, it also suggests that one site represents the primary tumor and the other a metastasis. Thus, there is no evidence to support the multifocal origin The case 1 alteration is not listed in COSMIC, but is equivalent to the simultaneous occurrence of both COSM43947 and COSM1716966.
c Not confirmed at second site.
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Identical TP53 mutations in bilateral HGSC of extrauterine high-grade serous carcinoma development (extremely rare exceptions in high-risk patients are discussed below). The p53 immunohistochemical staining results were also identical at the two sites of involvement, with all six cases where this could be evaluated showing a concordant mutation-type overexpression pattern.
The concept of 'field cancerization' (also known as field effect/change) introduced in 1950s is well established, though the mechanisms by which cancer might develop from a population of normal cells remain poorly understood. 26, 27 Field cancerization comprises a host of mechanisms that predispose an entire region of susceptible cells to the development of cancer through the acquisition of sequential genomic alterations. There is a need for more detailed research studies into the holistic nature of the field effect that include epigenetic, gene expression, and comprehensive mutational analyses. Related but distinct from this is the controversial issue of multifocal origin, that is, whether cancers can arise independently from each other within a cancerized field. This issue is not one of purely academic interest as the relationship between tumor at different sites has important implications for tumor staging, treatment, margin assessment, and risk of recurrence, as leaving behind a cancerized field of predisposed cells potentially places a patient at a higher risk of recurrence.
In tumors such as high-grade serous carcinoma, it could be argued that the impact of a field change is the susceptibility of cells at different sites, for example, tubal epithelium, ovarian surface epithelium, or pelvic peritoneum, to the same driver mutation, and therefore that the presence of identical TP53 mutations does not necessarily imply a single origin. Although this is a theoretical possibility, several factors argue against this mechanism in highgrade serous carcinoma. Of the 7 mutations observed in this small series, only those seen in cases 5 and 7 are 'hot spot' mutations that arguably could occur at a high frequency sporadically. The others are relatively rare and no plausible mechanism can be advanced for their independent occurrence at two different sites. Nevertheless, this does not disprove their simultaneous occurrence because of an underlying unrecognized mutation-specific risk factor. Such a mechanism can only be demonstrated through more detailed molecular analysis for demonstration of clonal evolution. Although this was not the remit of the current study, this has been amply investigated in previous elegant studies. These have shown consistent results demonstrating high-grade serous carcinoma to be characterized by tremendous genomic heterogeneity that arises at a very early stage, with a variety of shared mutations other than TP53 occurring at an early stage, and mutational and copy number changes occurring subsequently. 23, 28 This diversity between tumor from different anatomic sites occurs in the absence of any selection pressure resulting from chemotherapy. Despite the diversity, the study of spatial and temporal evolution patterns within individual cases overwhelmingly demonstrates origin from a single clone, 23 Identical TP53 mutations in bilateral HGSC TP53 mutation is established as a ubiquitous driver event, with frequent early loss of heterozygosity and resultant loss of the normal allele giving that clone a selection advantage. 28 The finding of an identical TP53 mutation in tumor at different disease sites is thereby widely accepted as valid proof of clonality and unifocal origin.
Having excluded the possibility that these are synchronous independent primary tumors, the question then arises as to which is the primary and which is the metastatic focus. This study is not able to offer a definite answer to this question. In the past, the larger size of the ovarian compared with the fallopian tube involvement would have been interpreted as evidence of the ovarian tumor being the primary (the dominant mass criterion for assignment of primary site) but it is now established that ovarian metastasis from a wide range of primary sites, for example, vermiform appendix, uterine cervix, endometrium, and stomach, can be much larger than the primary tumor and the dominant mass approach to ascertaining primary site is now discredited. As noted previously, in recent studies where extrauterine highgrade serous carcinoma was detected incidentally, in all examples of a unifocal tumor the tumor was located in the fallopian tube mucosa, providing compelling evidence that in most cases of extrauterine high-grade serous carcinoma showing both tubal and ovarian involvement or more extensive spread, the tube is likely to be the primary site. [9] [10] [11] There is also molecular evidence supporting tubal origin in most extrauterine high-grade serous carcinomas. Kuhn et al 21 performed mutational analyses on 29 cases of high-grade serous carcinoma and demonstrated a clonal relationship between 27 paired cases of serous tubal intraepithelial carcinoma and highgrade serous carcinoma. A study of telomere shortening in 12 paired cases of serous tubal intraepithelial carcinoma and high-grade serous carcinoma 29 found a significant shortening of telomeres in serous tubal intraepithelial carcinoma lesions compared with highgrade serous carcinoma. Telomere shortening is one of the earliest events in cancer progression and short telomeres cannot support the replication rates required by invasive cancers; therefore the finding of shortened telomeres in serous tubal intraepithelial carcinoma provides evidence that this is the earlier lesion. 30, 31 Centrosome number abnormality and CCNE1 amplification 32 was studied by the same group. CCNE1 encodes the gene for cyclin E1, the upregulation of which is thought to be an early event in malignant transformation; 33 increased cyclin E1 leads to chromosomal instability by causing aberrant centrosome duplication. 34, 35 They found an increase in CCNE1 copy number in serous tubal intraepithelial carcinoma lesions but there were greater centrosome numbers per tumor cell in the high-grade serous carcinoma compared with serous tubal intraepithelial carcinoma, providing further evidence that serous tubal intraepithelial carcinoma precedes high-grade serous carcinoma.
In two cases in the present series there were bilateral ovarian high-grade serous carcinomas with no tubal lesion found on complete examination of both tubes with additional deeper levels, 17 and one of the ovarian tumors is presumed to have been the primary neoplasm.
In the single case in this series with bilateral tubal mucosal involvement, it can be inferred that one tubal lesion is the primary tumor and the other represents metastasis. Eckert et al 28 performed nextgeneration (exome) sequencing in eight widely disseminated sporadic extrauterine high-grade serous carcinomas with serous tubal intraepithelial carcinoma and fallopian tube, ovarian, and omental high-grade serous carcinoma. They concluded, based on genomic analysis of disease progression, that in two cases the serous tubal intraepithelial carcinoma lesions were more likely to represent metastasis to the fallopian tube and that in a small proportion of cases, serous tubal intraepithelial carcinoma lesions can be metastatic. This is certainly the case for widely disseminated disease and bilateral tubal mucosal tumor, that is, one is metastatic, and is not surprising as other cancers have been reported to metastasize to the fallopian tube producing lesions microscopically identical to serous tubal intraepithelial carcinoma. 36, 37 Interestingly, a recent report of a case of bilateral tubal high-grade serous carcinoma in a patient with a BRCA1 germline mutation showed different TP53 mutations in the two tubes, suggestive of independent tumors in this high-risk patient; 38 identification of more than one TP53 mutation in a high-grade serous carcinoma has been reported in the past but this is infrequent, especially outside the setting of patients with genetic predisposition to development of high-grade serous carcinoma, that is, hereditary breast and ovarian cancer syndrome. 6, 7 The results presented herein have implications for FIGO staging. Using the current FIGO staging system for carcinomas of the ovary and fallopian tube, 39 cases 4, 5, and 7 would be considered FIGO stage IIA, whereas cases 1-3 would be classified as stage IB. This is not rational given that all represent a primary high-grade serous carcinoma with metastasis to the other adnexal site and logically all should be considered as stage II. There is further controversy about staging of cases exemplified by case 6 (serous tubal intraepithelial carcinoma with ovarian highgrade serous carcinoma) with some classifying this as a stage I ovarian primary and others as a stage IIA tubal primary. This is largely because of differing opinions as to whether serous tubal intraepithelial carcinoma should be considered a disease site for staging purposes. In a recent international survey, a case of serous tubal intraepithelial carcinoma with invasive ovarian high-grade serous carcinoma was classified as a stage I ovarian primary and a stage II tubal primary, respectively, by 27% and 45% of pathologists. 40 Among clinicians, an equal number of respondents (37%) would stage such a case as a stage I ovarian primary and a stage II tubal primary. 40 Based on our results, it appears logical to regard the ovaries and tubes (whether containing serous tubal intraepithelial carcinoma or invasive high-grade serous carcinoma) as representing two sites of disease, one primary and the other metastatic. Although the stage assignment is controversial in such patients, all would receive adjuvant chemotherapy, if medically fit, and hence treatment would not be influenced by the convention used to assign stage. Nevertheless, unless we stage these early cases consistently it will never become apparent whether these staging distinctions provide valid prognostic separation. This is particularly important as efforts toward early detection, opportunistic salpingectomy, and detailed pathological examination of the fallopian tubes are likely to result in an increase in the numbers of cases of low-stage extrauterine highgrade serous carcinoma diagnosed worldwide.
In conclusion, the consistent finding of identical TP53 mutations at both sites in this series of sporadic low-stage extrauterine high-grade serous carcinoma with only two sites of disease, located on opposite adnexa, argues strongly against multifocal origin of high-grade serous carcinoma as part of a field change. These findings should be taken into account for disease staging; we suggest that only single organconfined disease should be considered as stage I, as bilateral adnexal involvement indicates metastasis from one side to the other. We also believe that serous tubal intraepithelial carcinoma in combination with high-grade serous carcinoma at another site should be considered a disease site for the purposes of staging low-stage high-grade serous carcinoma as their clonal relationship, as established in our study, indicates the serous tubal intraepithelial carcinoma to be either the primary or a metastatic site of disease.
